comparemela.com
Home
Live Updates
FDA Issues CRL to Abeona for Potential RDEB Cell Therapy : comparemela.com
FDA Issues CRL to Abeona for Potential RDEB Cell Therapy
Abeona's pz-cel is up for indicated use to treat patients with recessive dystrophic epidermolysis bullosa.
Related Keywords
Amy Paller ,
Peter Marinkovich ,
Joyce Teng ,
Kunzmannk Amy Paller ,
Stanford University ,
Drug Administration ,
Abeona Therapeutics ,
Chemistry Manufacturing ,
Vish Seshardri ,
Northwestern Medicine ,
Stanford Bullous Disease ,
Epidermolysis Bullosa Gene Therapy ,
Published April ,
Abeona Therapeutics Provides Regulatory Update ,
New Therapies ,
Dystrophic Epidermolysis ,
Published March ,
What Pz Cel ,
Rdeb ,
Deb ,
Fda ,
Abeona ,
Pz Cel ,
Cell Therapy ,
Epidermolysis ,
Bullosa ,
Indication ,
comparemela.com © 2020. All Rights Reserved.